Reset filter
Keywords
Drugs, Investigational ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

224 Search results.

Relevance Rating New first Old first

The relationship of Glycine Transporter1 occupancy by GSK1018921 to plasma concentrations over time NCT00945503 - Day 1 - Vital Signs; 12-Lead ECG; Laboratory Results Data (Haematology, Clinical Chemistry) - Pre-Dose and 24h Post-Dose; Urinalysis - Pre-Dose and 24h Post-Dose; Randomisation Number; Investigational Product; Treatment Confirmation; PET Scan (2); fMRI Scan - Post-PET Scan; PET Scan (3); Pharmacokinetics - Blood

- 4/6/22 - 1 form, 16 itemgroups, 158 items, 1 language
Itemgroups: Administrative,Vital Signs,12-Lead ECG,Laboratory Results Data (Haematology) - Pre-Dose,Laboratory Results Data (Clinical Chemistry) - Pre-Dose,Urinalysis - Pre-Dose,Randomisation Number,Investigational Product,Treatment Confirmation,PET Scan (2),fMRI Scan - Post-PET Scan,PET Scan (3),Pharmacokinetics - Blood,Laboratory Results Data (Haematology) - 24hrs Post-Dose,Laboratory Result Data (Clinical Chemistry) - 24hrs Post-Dose,Urinalysis - 24hrs Post-Dose
Study ID: 109731 Clinical Study ID: 109731 Study Title: An adaptive PET study in healthy volunteers using 11C GSK931145 to establish the relationship of Glycine Transporter1 occupancy by GSK1018921 to plasma concentrations over time Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00945503 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK1018921 Study Indication: Schizophrenia

GW597599 and paroxetine on the pharmacokinetics of midazolam and dextromethorphan 100716 Pharmacogenetic Research, Prior And Concomitant Medication, Baseline Signs And Symptoms

- 9/20/21 - 1 form, 3 itemgroups, 28 items, 1 language
Itemgroups: Pharmacogenetic Research,prior medication,baseline signs and symptoms
Study ID: 100716 Clinical Study ID: NKP100716 Study Title: An open label repeat dose study to investigate the effect of GW597599 (15 mg) and paroxetine (10 mg) given in combination for 15 days on the pharmacokinetics of midazolam and dextromethorphan in healthy male and female volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: vestipitant Trade Name: paroxetine and vestipitant Study Indication: Depressive Disorder and Anxiety Disorders Documentation part: Pharmacogenetic Research, Prior And Concomitant Medication, Baseline Signs and Symptoms

Sumatriptan pharmacokinetics for TREXIMA/IMITREX ID 103629 - ECG Abnormalities

- 9/17/21 - 1 form, 8 itemgroups, 93 items, 1 language
Itemgroups: Administrative Data,12-Lead ECG Abnormalities,Rhythm,P-Wave Morphology,Conduction,Myocardial Infarction,Depolarisation/Repolarisation (QRS-T),ECG, Other abnormalities
This form documents the recorded abnormalities on ECG. To be filled in continously. Study ID: 103629 Clinical Study ID: TRX103629 Study Title: An open-label, randomized, 3-period crossover study to evaluate sumatriptan and naproxen pharmacokinetics for a combination tablet product containing sumatriptan/naproxen sodium followed by IMITREX™ (sumatriptan succinate) Injection 4mg administered using the IMITREX STATdose System and a sumatriptan/naproxen sodium tablet followed by IMITREX (sumatriptan succinate) Injection 6mg administered using the STATdose system compared with an IMITREX tablet 100mg followed by an IMITREX tablet 100mg Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00875784 Clinicaltrials.gov link: https://clinicaltrials.gov/ct2/show/NCT00875784 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: sumatriptan Trade Name: Imitrex ,Imiject ,Imigran; Imitrex,Imiject,Imigran Study Indication: Migraine Disorders

Sumatriptan pharmacokinetics for TREXIMA/IMITREX ID 103629 - Logs and Repeats

- 9/17/21 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Administrative Data,Adverse Event | Concomitant Medication | Evaluation
This form documents if any measurements were repeated during the study, if concomitant medications were taken or if any adverse events or ECG abnormalities occurred. To be assessed at study conclusion. Study ID: 103629 Clinical Study ID: TRX103629 Study Title: An open-label, randomized, 3-period crossover study to evaluate sumatriptan and naproxen pharmacokinetics for a combination tablet product containing sumatriptan/naproxen sodium followed by IMITREX™ (sumatriptan succinate) Injection 4mg administered using the IMITREX STATdose System and a sumatriptan/naproxen sodium tablet followed by IMITREX (sumatriptan succinate) Injection 6mg administered using the STATdose system compared with an IMITREX tablet 100mg followed by an IMITREX tablet 100mg Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00875784 Clinicaltrials.gov link: https://clinicaltrials.gov/ct2/show/NCT00875784 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: sumatriptan Trade Name: Imitrex ,Imiject ,Imigran; Imitrex,Imiject,Imigran Study Indication: Migraine Disorders

Relative bioavailability of four formulations of GSK lisinopril compared to Zestril (105533) - Session 1-4: Vital Signs; Pharmacokinetics Blood; Investigational Product; Treatment Confirmation; 12-Lead ECG

- 5/10/21 - 1 form, 17 itemgroups, 57 items, 1 language
Itemgroups: Administrative,Date of Visit/ Assessment,Randomisation (only Session 1),Vital Signs,Sitting Vital Signs - Predose,Orthostatic Vital Signs - Predose (Reading 1) - Supine for 5 mins,Orthostatic Vital Signs - Predose (Reading 2) - Sitting for 2 mins ,Orthostatic Vital Signs - Predose (Reading 3) - Standing for 3 mins ,Orthostatic Vital Signs - Post Dose - Sitting,Orthostatic Vital Signs - 10 Hours (Reading 1) - Supine for 5 mins,Orthostatic Vital Signs - 10 Hours (Reading 2) - Sitting for 2 mins ,Orthostatic Vital Signs - 10 Hours (Reading 3) - Standing for 3 mins ,Pharmacokinetics Blood - Dosing Date and Time,Pharmacokinetics Blood,Investigational Product,Treatment Confirmation,12-Lead ECG (only Session 4)
Study ID: 105533 Clinical Study ID: 105533 Study Title: A randomized, open-label, single-dose, four period cross-over study to evaluate the relative bioavailability of four formulations of GSK lisinopril compared to Zestril, and to compare over-incapsulated Zestril to Zestril Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Carvedilol Trade Name: Zestril Study Indication: Hypertension

Efficacy and Safety of Single Dose Intranasal GSK1004723 in an Allergen Challenge Chamber NCT00824356 - Visit 1, 3, 5 - Randomisation Number; Vital Signs; Nasal Inspection; Challenge Date and Time; Investigational Product

- 2/25/21 - 1 form, 9 itemgroups, 29 items, 1 language
Itemgroups: Date of Visit,Randomisation Number (Vsit 1),Vital Signs - Challenge Date and Time (Visit 1, 3, 5),Vital Signs - Start of Challenge (Visit 1, 3, 5),Nasal Inspection (Visit 1, 3, 5),Challenge Date and Time - Challenge (0 - 6 Hr) (Visit 1, 3, 5),Investigational Product (Dose) - Challenge Date and Time (Visit 1, 3, 5),Investigational Product - Date/time of dose (Visit 1, 3, 5),Investigational Product - Treatment Confirmation (Visit 1, 3, 5)
Study ID: 110159 Clinical Study ID: 110159 Study Title: A Randomised, Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Assess the Efficacy and Safety of Single Dose Intranasal GSK1004723 Compared With Placebo in an Allergen Challenge Chamber in Male Subjects With Seasonal Allergic Rhinitis Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00824356 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Placebo, GSK1004723 (200mg), GSK1004723 (1000mg) Study Indication: Allergic Rhinitis

Effect of one week repeat dosing of GW685698X and FP on serum cortisol (103096) - Treatment Period 1- 5 - Investigational Product; Treatment Confirmation; Carbon Monoxide Test; Urine Test for Drugs of Abuse; Vital Signs; 12-Lead ECG; Pulmonary Function Test

- 2/8/21 - 1 form, 11 itemgroups, 54 items, 1 language
Itemgroups: Administrative,Investigational Product Day 1 - 7,Treatment Corfirmation Day 1 - 7,Carbon Monoxide Test - Day 6 PM,Urine Test for Drugs of Abuse,Urine Test for Drugs of Abuse ,Vital Signs - Day 7,12-Lead ECG - Day 7,12-Lead ECG Abnormalities - Day 7,12-Lead ECG Abnormalities - Day 7,Pulmonary Function Test - Day 7
Study ID: 103096 Clinical Study ID: 103096 Study Title: A randomised, double blind, placebo controlled, incomplete block, five-way cross-over study to investigate the effect of one week repeat dosing of GW685698X and FP on twenty-four hour serum cortisol in healthy subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Fluticasone Furoate;Fluticasone Propionate Trade Name: Fluticasone Furoate;Fluticasone Propionate Study Indication: Asthma

Safety, tolerability and pharmacokinetics of GSK573719 and placebo formulated with the excipient magnesium stearate NCT00803673 - Part 2, Period 2, Cohort 1 Days 2-6: Investigational Product; ECG; Vital Signs; Pulmonary Function Test

- 1/2/21 - 1 form, 33 itemgroups, 122 items, 1 language
Itemgroups: Date of visit,Investigational Product (Dose) (Part 2 Period 2),ECG,ECG - Day 2 Dose (Part 2 Period 2),ECG - Day 2 Dose (Part 2 Period 2,ECG - Day 3 Dose (Part 2 Period 2),ECG - Day 3 Dose (Part 2 Period 2),ECG - Day 4 Dose (Part 2 Period 2),ECG - Day 4 Dose (Part 2 Period 2),ECG - Day 5 Dose (Part 2 Period 2),ECG - Day 5 Dose (Part 2 Period 2),ECG - Day 6 Dose (Part 2 Period 2),ECG - Day 6 Dose (Part 2 Period 2),Vital Signs - Day 2 Dose (Part 2 Period 2),Vital Signs - Day 2 Dose (Part 2 Period 2),Vital Signs - Day 3 Dose (Part 2 Period 2),Vital Signs - Day 3 Dose (Part 2 Period 2),Vital Signs - Day 4 Dose (Part 2 Period 2),Vital Signs - Day 4 Dose (Part 2 Period 2),Vital Signs - Day 5 Dose (Part 2 Period 2),Vital Signs - Day 5 Dose (Part 2 Period 2),Vital Signs - Day 6 Dose (Part 2 Period 2),Vital Signs - Day 6 Dose (Part 2 Period 2),Pulmonary Function Tests - Day 2 Dose (Part 2 Period 2),Pulmonary Function Tests - 2 hours Post-Dose, Day 2 (Part 2 Period 2),Pulmonary Function Tests - Day 3 Dose (Part 2 Period 2),Pulmonary Function Tests - 2 hours Post-Dose, Day 3 (Part 2 Period 2),Pulmonary Function Tests - Day 4 Dose (Part 2 Period 2),Pulmonary Function Tests - 2 hours Post-Dose, Day 4 (Part 2 Period 2),Pulmonary Function Tests - Day 5 Dose (Part 2 Period 2),Pulmonary Function Tests - 2 hours Post-Dose, Day 5 (Part 2 Period 2),Pulmonary Function Tests - Day 6 Dose (Part 2 Period 2),Pulmonary Function Tests - 2 hours Post-Dose, Day 6 (Part 2 Period 2)
Study ID: 110106 Clinical Study ID: 110106 Study Title: A single centre, randomized, double-blind, dose ascending, placebo-controlled study, in two parts, to evaluate the safety, tolerability and pharmacokinetics of escalating single and repeat inhaled doses of GSK573719 and placebo formulated with the excipient magnesium stearate, in healthy subjects and in a healthy population of Cytochrome P450 Isoenzyme 2D6 poor metabolisers. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00803673 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK573719, Placebo Study Indication: Pulmonary Disease, Chronic Obstructive

Safety, tolerability and pharmacokinetics of GSK573719 and placebo formulated with the excipient magnesium stearate NCT00803673 - Part 2, Period 2, Cohort 1 Day 1: Local Laboratory; Investigational Product; ECG; Vital Signs; Pulmonary Function Tests; Holter Summary; Holter Abnormalities

- 1/2/21 - 1 form, 16 itemgroups, 52 items, 1 language
Itemgroups: Date of visit,Local Laboratory - Haematology (Part 2 Period 4),Local Laboratory - Haematology (Part 2 Period 4),Local Laboratory - Clinical Chemistry (Part 2 Period 4),Local Laboratory - Clinical Chemistry (Part 2 Period 4),Investigational Product (Dose) (Part 2 Period 4),ECG (Part 2 Period 4),ECG (Part 2 Period 4),Vital Signs (Part 2 Period 4),Vital Signs (Part 2 Period 4),Local Laboratory - Haematology (24Hr Lab) (Part 2 Period 4),Local Laboratory - Haematology (24 Hr Lab) (Part 2 Period 4),Local Laboratory - Clinical Chemistry (24 Hr Lab) (Part 2 Period 4),Local Laboratory - Clinical Chemistry (24 Hr Lab) (Part 2 Period 4),Pulmonary Function Tests (Part 2 Period 4),Pulmonary Function Tests (Part 2 Period 4)
Study ID: 110106 Clinical Study ID: 110106 Study Title: A single centre, randomized, double-blind, dose ascending, placebo-controlled study, in two parts, to evaluate the safety, tolerability and pharmacokinetics of escalating single and repeat inhaled doses of GSK573719 and placebo formulated with the excipient magnesium stearate, in healthy subjects and in a healthy population of Cytochrome P450 Isoenzyme 2D6 poor metabolisers. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00803673 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK573719, Placebo Study Indication: Pulmonary Disease, Chronic Obstructive

Safety, tolerability and pharmacokinetics of GSK573719 and placebo formulated with the excipient magnesium stearate NCT00803673 - Part 2, Period 1, Cohort 1: Local Laboratory; Investigational Product; ECG, Vital Signs; Pharmacokinetics; SUmmary Holter; Holter Abnormalities; Pulmonary Function Tests

- 1/2/21 - 1 form, 21 itemgroups, 84 items, 1 language
Itemgroups: Date of Visit,Local Laboratory - Haematology (Period 1),Local Laboratory - Haematology (Period 1),Local Laboratory - Clinical Chemistry (Period 1),Local Laboratory - Clinical Chemistry (Period 1),Investigational Product (Dose) (Period 1),ECG (Period 1),Vital Signs (Period 1),Local Laboratory - Haematology (24Hr Lab) (Period 1),Local Laboratory - Haematology (24 Hr Lab) (Period 1),Local Laboratory - Clinical Chemistry (24 Hr Lab) (Period 1),Local Laboratory - Clinical Chemistry (24 Hr Lab) (Period 1),Pharmacokinetics Blood (Period 1),Pharmacokinetics Blood (Period 1),Pharmacokinetics Urine (Period 1),Pharmacokinetics Urine (Period 1),Summary Holter (Period 1),Summary Holter (Period 1) (Pre-Dose - 24 hours),Holter Abnormalities (Period 1),Holter Abnormalities (Period 1),Pulmonary Function Tests (Period 1)
Study ID: 110106 Clinical Study ID: 110106 Study Title: A single centre, randomized, double-blind, dose ascending, placebo-controlled study, in two parts, to evaluate the safety, tolerability and pharmacokinetics of escalating single and repeat inhaled doses of GSK573719 and placebo formulated with the excipient magnesium stearate, in healthy subjects and in a healthy population of Cytochrome P450 Isoenzyme 2D6 poor metabolisers. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00803673 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK573719, Placebo Study Indication: Pulmonary Disease, Chronic Obstructive

Safety, tolerability and pharmacokinetics of GSK573719 and placebo formulated with the excipient magnesium stearate NCT00803673 - Part 2, Period 2, Cohort 1 Days 7, 8: Investigational Product; ECG; Vital Signs; Pulmonary Function Tests; Local Laboratory; Pharmacokinetics; Summary Holter; Holter Abnormalities

- 1/2/21 - 1 form, 20 itemgroups, 72 items, 1 language
Itemgroups: Date of visit,Investigational Product (Dose) (Part 2 Period 2),ECG (Part 2 Period 2),ECG (Part 2 Period 2),Vital Signs (Part 2 Period 2),Vital Signs (Part 2 Period 2),Pulmonary Function Tests (Part 2 Period 2),Pulmonary Function Tests (Part 2 Period 2),Local Laboratory - Haematology (24Hr Lab) (Part 2 Period 2),Local Laboratory - Haematology (24 Hr Lab) (Part 2 Period 2),Local Laboratory - Clinical Chemistry (24 Hr Lab) (Part 2 Period 2),Local Laboratory - Clinical Chemistry (24 Hr Lab) (Part 2 Period 2),Pharmacokinetics Blood (Part 2 Period 2),Pharmacokinetics Blood (Part 2 Period 2),Pharmacokinetics Urine (Part 2 Period 2),Pharmacokinetics Urine (Part 2 Period 2),Summary Holter (Part 2 Period 2),Summary Holter (Part 2 Period 2) (Pre-Dose - 24 hours),Holter Abnormalities (Part 2 Period 2),Holter Abnormalities (Part 2 Period 2)
Study ID: 110106 Clinical Study ID: 110106 Study Title: A single centre, randomized, double-blind, dose ascending, placebo-controlled study, in two parts, to evaluate the safety, tolerability and pharmacokinetics of escalating single and repeat inhaled doses of GSK573719 and placebo formulated with the excipient magnesium stearate, in healthy subjects and in a healthy population of Cytochrome P450 Isoenzyme 2D6 poor metabolisers. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00803673 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK573719, Placebo Study Indication: Pulmonary Disease, Chronic Obstructive

Safety, tolerability and pharmacokinetics of GSK573719 and placebo formulated with the excipient magnesium stearate NCT00803673 - Part 2, Period 3, Cohort 1: Local Laboratory; Investigational Product; ECG, Vital Signs; Pharmacokinetics; SUmmary Holter; Holter Abnormalities; Pulmonary Function Tests

- 1/2/21 - 1 form, 21 itemgroups, 84 items, 1 language
Itemgroups: Date of Visit,Local Laboratory - Haematology (Period 3),Local Laboratory - Haematology (Period 3),Local Laboratory - Clinical Chemistry (Period 3),Local Laboratory - Clinical Chemistry (Period 3),Investigational Product (Dose) (Period 3),ECG (Period 3),Vital Signs (Period 3),Local Laboratory - Haematology (24Hr Lab) (Period 3),Local Laboratory - Haematology (24 Hr Lab) (Period 3),Local Laboratory - Clinical Chemistry (24 Hr Lab) (Period 3),Local Laboratory - Clinical Chemistry (24 Hr Lab) (Period 3),Pharmacokinetics Blood (Period 3),Pharmacokinetics Blood (Period 3),Pharmacokinetics Urine (Period 3),Pharmacokinetics Urine (Period 3),Summary Holter (Period 3),Summary Holter (Period 3) (Pre-Dose - 24 hours),Holter Abnormalities (Period 3),Holter Abnormalities (Period 3),Pulmonary Function Tests (Period 3)
Study ID: 110106 Clinical Study ID: 110106 Study Title: A single centre, randomized, double-blind, dose ascending, placebo-controlled study, in two parts, to evaluate the safety, tolerability and pharmacokinetics of escalating single and repeat inhaled doses of GSK573719 and placebo formulated with the excipient magnesium stearate, in healthy subjects and in a healthy population of Cytochrome P450 Isoenzyme 2D6 poor metabolisers. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00803673 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK573719, Placebo Study Indication: Pulmonary Disease, Chronic Obstructive

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial